PharmaEngine (4162.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Taiwan · ISIN TW0004162003
PharmaEngine financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.52 bn TWD | 911.42 m TWD |
| Gross profit | 2.48 bn TWD | 859.56 m TWD |
| Operating income | 2.05 bn TWD | 425.48 m TWD |
| EBIT | 2.16 bn TWD | 509.43 m TWD |
| Net income | 1.75 bn TWD | 387.64 m TWD |
| Diluted EPS – continuing operations | 12.19 TWD | 2.74 TWD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
More stocks
- Ucore Rare Metals Inc (UCU.V)
- Thrace Plastics Holding and Commercial S.A (PLAT.AT)
- Cashbox Partyworld Co. Ltd. (8359.TWO)
- All Iron Re I Socimi Sa (YAI1.MC)
- ALLIANCE ENTERTAINMENT HOLDING CORP (AENT)
- RGC RESOURCES INC (RGCO)
- Jiin Yeeh Ding Enterprise Co Ltd (8390.TWO)
- HengFeng Information Technology Co Ltd (300605.SZ)
- Elnusa Tbk (ELSA.JK)
- Advanced Ceramic X (3152.TWO)
- Hercules Metals Corp. (BIG.V)
- PLINTAS (5320.KL)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.